|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"park k"
Showing items 51-60 of 66 (7 Page(s) Totally)
<< < 1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 臺大學術典藏 |
2020-05-25T07:35:09Z |
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
|
Viteri S; Chang G.-C; Chiari R; Cho B.C; Ciardiello F; Curigliano G; Hida T; Lee D.H; Lim W.T.D; Chia-Chi Lin; Martinez A; Murakami H; Natsume I; Nishio M; Paz-Ares L; Soo R.A; Cattan V; Gandossi E; Heck H; Park K. |
| 臺大學術典藏 |
2020-04-27T08:45:04Z |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
|
Park K.; Vansteenkiste J.; Lee K.H.; Pentheroudakis G.; Zhou C.; Prabhash K.; Seto T.; Voon P.J.; Tan D.S.W.; Yang J.C.H.; Wang J.; Babu K.G.; Douillard J.-Y.; Yoshino T.; Peters S.; Ahn H.K.; Kim T.-Y.; Ahn Y.C.; Senan S.; CHIA-HSIEN CHENG; Chua K.L.M.; Alip A.; Nakayama Y.; Park K.;Vansteenkiste J.;Lee K.H.;Pentheroudakis G.;Zhou C.;Prabhash K.;Seto T.;Voon P.J.;Tan D.S.W.;Yang J.C.H.;Wang J.;Babu K.G.;Nakayama Y.;Alip A.;Chua K.L.M.;Chia-Hsien Cheng;Senan S.;Ahn Y.C.;Kim T.-Y.;Ahn H.K.;Peters S.;Yoshino T.;Douillard J.-Y. |
| 臺大學術典藏 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Shaw A.T.; Passos V.Q.; Chen Z.; Viraswami-Appanna K.; Spigel D.R.; Scagliotti G.V.; Mok T.; Su W.-C.; Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Nishio M.;Felip E.;Orlov S.;Park K.;Chong-Jen Yu;Tsai C.-M.;Cobo M.;Mckeage M.;Su W.-C.;Mok T.;Scagliotti G.V.;Spigel D.R.;Viraswami-Appanna K.;Chen Z.;Passos V.Q.;Shaw A.T. |
| 國立成功大學 |
2020 |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio, M.;Felip, E.;Orlov, S.;Park, K.;Yu, C.-J.;Tsai, C.-M.;Cobo, M.;McKeage, McKeage M.;Su, W.-C.;Mok, T.;Scagliotti, G.V.;Spigel, D.R.;Viraswami-Appanna, K.;Chen, Z.;Passos, V.Q.;Shaw, A.T. |
| 臺大學術典藏 |
2019 |
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Nakagawa K.;Garon E.B.;Seto T.;Nishio M.;Ponce Aix S.;Paz-Ares L.;Chiu C.-H.;Park K.;Novello S.;Nadal E.;Imamura F.;Yoh K.;Jin-Yuan Shih;Au K.H.;Moro-Sibilot D.;Enatsu S.;Zimmermann A.;Frimodt-Moller B.;Visseren-Grul C.;Reck M.;Chu Q.;Cortot A.;Pujol J.-L.;Fabre E.;Lamour C.;Bischoff H.;Kollmeier J.;Kimmich M.;Engel-Riedel W.;Hammerschmidt S.;Sch?Tte W.;Syrigos K.;Ho J.C.M.;Au K.-H.;Ardizzoni A.;Pasello G.;Gregorc V.;Del Conte A.;Galetta D.;Takahashi T.;Kumagai T.;Hotta K.;Goto Y.;Hosomi Y.;Sakai H.;Takiguchi Y.;Kim Y.H.;Kurata T.;Yamaguchi H.;Daga H.;Okamoto I.;Satouchi M.;Ikeda S.;Kasahara K.;Atagi S.;Azuma K.;Aoe K.;Horio Y.;Yamamoto N.;Tanaka H.;Watanabe S.;Nogami N.;Ozaki T.;Koyama R.;Hirashima T.;Kaneda H.;Tomii K.;Fujita Y.;Seike M.;Nishimura N.;Kato T.;Ichiki M.;Saka H.;Hirano K.;Nakahara Y.;Sugawara S.;Kim S.-W.;Min Y.J.;Lee H.W.;Kang J.-H.;An H.J.;Lee K.H.;Kim J.-S.;Lee G.-W.;Lee S.Y.;Alexandru A.;Udrea A.A.;Juan-Vidal ?.;Nadal-Alforja E.;Gil-Bazo I.;Ponce-Aix S.;Rubio-Viqueira B.;Alonso Garcia M.;Felip Font E.;Fuentes Pradera J.;Coves Sarto J.;Lin M.-C.;Su W.-C.;Hsia T.-C.;Chang G.-C.;Wei Y.-F.;Su J.;Cicin I.;Goksel T.;Harputluoglu H.;Ozyilkan O.;Henning I.;Popat S.;Hatcher O.;Mileham K.;Acoba J.;Garon E.;Jung G.;Raj M.;Martin W.;Dakhil S.; Hirano K.; Nakahara Y.; Saka H.; Ichiki M.; Kato T.; Nishimura N.; Seike M.; Fujita Y.; Tomii K.; Kaneda H.; Hirashima T.; Koyama R.; Aoe K.; Horio Y.; Yamamoto N.; Tanaka H.; Watanabe S.; Nogami N.; Ozaki T.; Azuma K.; Atagi S.; Sch?tte W.; Syrigos K.; Ho J.C.M.; Au K.-H.; Ardizzoni A.; Pasello G.; Gregorc V.; Del Conte A.; Galetta D.; Takahashi T.; Kumagai T.; Hotta K.; Goto Y.; Hosomi Y.; Sakai H.; Takiguchi Y.; Kim Y.H.; Kurata T.; Yamaguchi H.; Daga H.; Okamoto I.; Satouchi M.; Ikeda S.; Kasahara K.; Nakagawa K.; Garon E.B.; Seto T.; Nishio M.; Ponce Aix S.; Paz-Ares L.; Chiu C.-H.; Park K.; Novello S.; Nadal E.; Imamura F.; Yoh K.; JIN-YUAN SHIH; Au K.H.; Moro-Sibilot D.; Enatsu S.; Zimmermann A.; Frimodt-Moller B.; Visseren-Grul C.; Reck M.; Chu Q.; Cortot A.; Pujol J.-L.; Fabre E.; Lamour C.; Bischoff H.; Kollmeier J.; Kimmich M.; Engel-Riedel W.; Hammerschmidt S.; Wei Y.-F.; Chang G.-C.; Hsia T.-C.; Su W.-C.; Lin M.-C.; Coves Sarto J.; Fuentes Pradera J.; Felip Font E.; Alonso Garcia M.; Rubio-Viqueira B.; Ponce-Aix S.; Gil-Bazo I.; Nadal-Alforja E.; Juan-Vidal ?.; Sugawara S.; Kim S.-W.; Min Y.J.; Lee H.W.; Kang J.-H.; An H.J.; Lee K.H.; Kim J.-S.; Lee G.-W.; Lee S.Y.; Alexandru A.; Udrea A.A.; Su J.; Cicin I.; Goksel T.; Harputluoglu H.; Ozyilkan O.; Henning I.; Popat S.; Hatcher O.; Mileham K.; Acoba J.; Garon E.; Jung G.; Raj M.; Martin W.; Dakhil S. |
| 國立成功大學 |
2018 |
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer
|
Gerber, D.E.;Horn, L.;Boyer, M.;Sanborn, R.;Natale, R.;Palmero, R.;Bidoli, P.;Bondarenko, I.;Germonpre, P.;Ghizdavescu, D.;Kotsakis, A.;Lena, H.;Losonczy, G.;Park, K.;Su, W.-C.;Tang, M.;Lai, J.;Kallinteris, N.L.;Shan, J.S.;Reck, M.;Spigel, D.R. |
| 國立臺灣大學 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D.; 楊志新 |
| 臺大學術典藏 |
2016 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
|
Schuler, M.;Yang, J. C. -H.;Park, K.;Kim, J. -H.;Bennouna, J.;Chen, Y. -M.;Chouaid, C.;De Marinis, F.;Feng, J. -F.;Grossi, F.;Kim, D. -W.;Liu, X.;Lu, S.;Strausz, J.;Vinnyk, Y.;Wiewrodt, R.;Zhou, C.;Wang, B.;Chand, V. K.;Planchard, D.; 楊志新; Schuler, M.; Yang, J. C. -H.; Park, K.; Kim, J. -H.; Bennouna, J.; Chen, Y. -M.; Chouaid, C.; De Marinis, F.; Feng, J. -F.; Grossi, F.; Kim, D. -W.; Liu, X.; Lu, S.; Strausz, J.; Vinnyk, Y.; Wiewrodt, R.; Zhou, C.; Wang, B.; Chand, V. K.; Planchard, D. |
| 臺北醫學大學 |
2008 |
The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer.
|
Chang MH;Ahn JS; Lee J; Kim KH; Park YH; Han J;Ahn MJ;Park K |
Showing items 51-60 of 66 (7 Page(s) Totally)
<< < 1 2 3 4 5 6 7 > >>
View [10|25|50] records per page
|
